Patients with DLBCL (N=32)Poster: 284

**METHODS**

- **Key Inclusion Criteria**
  - Relapsed or refractory FL (Grade 1, 2, or 3a) or DLBCL
  - At least 11.6-dimensionally measurable lesion defined as >1.5 cm in long axis
  - Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2 for pts with prior bendamustine
  - Response assessed every 3 cycles, and complete response (CR) at end of study by investigator or independent review committee (IRC) (IRC data not available)

- **Key Exclusion Criteria**
  - Prior autologous stem cell transplant
  - Autologous transplant >100 days from C1D1
  - Eligibility for autologous stem cell transplant
  - History of transformation of low-grade lymphomas to DLBCL
  - Current Grade 1 peripheral neuropathy (PN)

- **Phase 2 Study Design**
  - Phase II and Phase III studies
  - Primary objectives
  - Secondary objectives
  - Safety and tolerability of Pola + BR or BG
  - Identified the recommended Phase II dose (RP2D) of Pola when given in combination with BR or BG
  - Response rate assessed every 3 cycles, and complete response (CR) at end of study by investigator or independent review committee (IRC) (IRC data not available)

- **DISCLOSURES**
  - All data and personal health information (PHI) are de-identified as required by HIPAA
  - PHI includes names, dates of birth, phone numbers, social security numbers
  - ARTICLE 6. All data and personal health information (PHI) are de-identified as required by HIPAA
  - PHI includes names, dates of birth, phone numbers, social security numbers

- **ACKNOWLEDGEMENTS**
  - All study participants, investigators, and research associates
  - All sponsors and collaborators

- **REFERENCES**
  - All references and supporting documentation

- **CONCLUSIONS**
  - All conclusions and recommendations

- **Figure 4: Time to PFS Events in FL Pts (A) and DLBCL Pts (B)**
  - Table 3: Grade 3/4 Adverse Events (≥10% patients)
  - Table 4: Peripheral Neuritis
  - Table 5: Investigator-Assessed Response by PET/CT*

- **RESULTS**
  - Of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)

- **OBJECTIVES**
  - Primary
  - Secondary

- **BACKGROUND**
  - Patients with polyclonal, antibody-drug conjugate (ADC) designed for the targeted delivery of the potent microtubule (MTB) inhibitor monomethyl auristatin E (MMAE) to select CD79b-expressing lymphoma cells
  - Pola combined with rituximab (R) has previously demonstrated promising response rates in pts with R/R FL or DLBCL. The addition of bendamustine (B) to Pola-R and substitution of obinutuzumab (G) for R for improved outcomes in these pts
  - As of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)

- **Figure 1: Pola Mode of Action**
  - Targets to B-cell malignancies
  - Disrupts Microtubule Anti-CD79b Linker

- **Figure 2: Study Design**
  - Safety run-in Phase: Pola + BR or BG
  - Phase II Expansion: Pola + BR or BG

- **Table 2: Therapy Delivered**
  - Characteristics
  - Pola + BR vs BR in R/R FL and R/R DLBCL. Results from these arms of the study reported in

- **Table 3: Grade 3/4 Adverse Events (≥10% patients)**
  - Hematological, n (%)
  - Infusion-related events, n (%)
  - Non-hematological, n (%)

- **Table 4: Peripheral Neuritis**
  - History of prior PN, n (%)
  - Ongoing PR at study entry, n (%)
  - All grade, n (%)
  - Grade 2, n (%)

- **Table 5: Investigator-Assessed Response by PET/CT**
  - ORR, n (%)
  - Best Objective Response
  - Table 6: Duration of response, mo (median)

- **RESULTS**
  - As of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)

- **Table 1: Baseline Characteristics**
  - Characteristics
  - Pola + BR vs BR in R/R FL and R/R DLBCL. Results from these arms of the study reported in

- **RESULTS**
  - As of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)

- **RESULTS**
  - As of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)

- **RESULTS**
  - As of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)

- **RESULTS**
  - As of 28 February 2017, 24 pts (12 FL, 12 DLBCL) were enrolled in the safety run-in and 20 FL and 21 R/R FL pts were enrolled into the expansion cohort
  - Safety run-in (n=24) and EXP FL Pola (n=20)